MapLight Therapeutics, Inc. (MPLT)
Healthcare
- Fundamental
- 2
- Sentiment
- 4
- Technical
- 1
Do Nothing: fundamentalScore is 2 (below the required floor of 3) and the stock also printed a 64.49% regular-open gap versus the prior regular close, making the protective stop unprotectable for a fresh long.
Company overview
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for severe central nervous system disorders. Its pipeline includes candidates targeting schizophrenia, Alzheimer's disease psychosis, autism spectrum disorder, and Parkinson's disease. The company also utilizes a proprietary platform to identify and modulate neural circuits linked to these conditions.
Fundamental
weakMapLight's fundamentals are speculative due to its pre-revenue status and reliance on clinical outcomes.
Clinical-stage biotech with zero revenue and high cash burn. SEC 10-Q filed 2026-05-14 shows strong liquidity ($395.2M cash + investments at 2026-03-31; current liabilities $14.3M implying ~23x current ratio) and management expects runway into 2027, but the company remains dependent on future clinical/regulatory success. An 8-K filed 2026-07-27 disclosed positive Phase 2 ZEPHYR topline results for ML-007C-MA in schizophrenia (primary endpoint met), which improves the outlook but does not remove the binary nature of the story. FundamentalScore = 2 (Do Nothing / high-risk).
Sentiment
goodRecent positive Phase 2 trial results for ML-007C-MA in schizophrenia improve sentiment.
The 2026-07-27 GlobeNewswire release reporting positive topline Phase 2 ZEPHYR results for ML-007C-MA in schizophrenia is a fresh, announced bullish product catalyst that likely isn’t fully digested yet. Media sentiment over the last ~14d is mildly positive but slightly softer than the prior 30–90d baseline, and the legal/regulatory screen is clear (Red-Flag Screen clean).
Technical
very weakThe stock is in a strong downward trend with oversold indicators and significant volatility.
Massive gap-down breakdown on heavy distribution leaves MPLT far below SMA20/50/200, EMA9/21 and daily VWAP. RSI 20.50 and Williams %R -100.00 are oversold, but MACD is below zero and ADX 51.91 confirms that the dominant short-term trend is still down, not reversing.
You’re looking at 2026-07-27 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.